

# EU Health Landscape: EMA Recommendations, AMR Funding, and Vaccine C

EU Health · Practice Test · 10 Questions

---

**1. Which of the following new medicines was recommended for approval by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in the latter half of April 2026?**

- A) A new treatment for familial chylomicronaemia syndrome
- B) A novel therapy for advanced pancreatic cancer
- C) An innovative drug for type 2 diabetes management
- D) A breakthrough treatment for rare autoimmune disorders

**2. The European Commission announced a significant pledge towards global health initiatives at the One Health Summit in Lyon. What was the total amount pledged to the Global Fund to defeat HIV, tuberculosis, and malaria?**

- A) EUR500 million
- B) EUR700 million
- C) EUR900 million
- D) EUR1 billion

**3. The European Medicines Agency (EMA) recently established a new advisory group aimed at bolstering vaccine confidence. What is the primary objective of this group?**

- A) To fast-track the approval process for new vaccines
- B) To conduct independent clinical trials for vaccine efficacy
- C) To counter vaccine hesitancy and enhance vaccine perception
- D) To negotiate vaccine prices with pharmaceutical companies

**4. In April 2026, the European Centre for Disease Prevention and Control (ECDC) released its Communicable Disease Threats Report (CDTR). Which of the following diseases was NOT specifically highlighted in the report covering April 25-30, 2026?**

- A) Influenza
- B) Cholera
- C) Chikungunya virus disease
- D) Ebola virus disease

**5. The Horizon Europe 'Health' calls for proposals for 2026 have been published. One of the topics under the destination 'Tackling diseases and reducing disease burden' focuses on the prevention, diagnosis, and management of what specific health issue?**

- A) Rare genetic disorders
- B) Antimicrobial resistance
- C) Post-infection long-term conditions
- D) Cardiovascular diseases in adolescents

**6. A recent announcement from the European Commission detailed investments to strengthen health security in Africa and Europe. How much was specifically allocated to combat antimicrobial resistance (AMR) through research and development of new antibiotics and medical countermeasures?**

- A) EUR30 million
- B) EUR46.5 million
- C) EUR50 million
- D) EUR70 million

**7. The European Medicines Agency (EMA) recommends a positive opinion for Sanofi's Cenrifki (tolebrutinib) for which specific medical condition?**

- A) Relapsing-remitting multiple sclerosis
- B) Secondary progressive multiple sclerosis without relapses
- C) Pediatric multiple sclerosis
- D) Primary progressive multiple sclerosis

**8. The European Public Health Week (EUPHW) 2026, led by EUPHA, has announced its daily themes. Which of the following is NOT one of the overarching daily themes for EUPHW 2026?**

- A) Aligning all policies with public health
- B) Prioritising equity through inclusive health investments
- C) Strengthening and supporting the health workforce
- D) Harmonising pharmaceutical pricing across member states

**9. Regarding the Horizon Europe 'Health' calls for proposals for 2026, which topic specifically addresses understanding sex and/or gender-specific mechanisms of cardiovascular diseases?**

- A) HORIZON-HLTH-2026-01-STAYHLTH-02
- B) HORIZON-HLTH-2026-01-ENVHLTH-01
- C) HORIZON-HLTH-2026-01-DISEASE-11
- D) HORIZON-HLTH-2026-01-CARE-03

**10. The European Medicines Agency (EMA) has been consulting on a new testing method to reduce animal use in medicines development. What type of method is this consultation focused on?**

- A) In-vitro testing using human cell cultures
- B) Computational modeling and simulation
- C) Virtual control groups
- D) Organ-on-a-chip technology